This cluster is routine and non-informative. The dollar amount is trivial relative to market cap, all sales are by C-suite insiders but at a scale consistent with liquidity/vesting-driven selling (no cluster buys to contrast). The historical calibration on MAZE shows a 38% win rate at T+20 with negative alpha, further supporting a neutral read. No action warranted.
Price Chart
Executive Summary
Four top Maze Therapeutics insiders — CEO, President/R&D/CMO, GC, and CSBO — sold a combined ~$498K in open-market shares over a 2-day window near $26.38, with the CEO alone accounting for $260K. The cluster is entirely sells, no buys, and the $498K represents ~0.036% of the $1.4B market cap, falling below the 0.1% triviality threshold. Historical calibration on this ticker shows a 38% win rate at T+20 with negative average alpha, suggesting the market has not rewarded prior directional calls on MAZE, but the cross-filing actuarial verdicts flag this cluster as an amplifier when combined with other context types — no such amplifying context is present here, so the filing stands on its own as a routine, low-signal cluster of liquidity-driven sales.
Key Financial Metrics
Key Facts
- Four C-suite insiders sold shares in a 2-day window (Sep 1-2, 2026): CEO Jason Coloma ($260K), President/R&D/CMO Harold Bernstein ($118K), GC Courtney Phillips ($46K), CSBO Atul Dandekar ($74K)
- Total open-market sales: ~$498K, representing ~0.036% of the $1.4B market cap — well below the 0.1% triviality threshold
- No insider purchases in the cluster; all transactions are open-market sells (code S)
- President Bernstein also exercised 20,000 derivative shares at $0 (non-cash) and 16,141 shares at $10.42 on Sep 1, then sold 16,141 shares on the same day — a typical cashless exercise pattern
- Prior 30-day insider activity shows 10 sells totaling $621K, consistent with routine selling patterns
Financial Impact
~$498K in insider sales, 0.036% of market cap — immaterial
Risk Factors
- Insider selling could accelerate if the stock continues to trade near $26-27, but current levels are not alarming given the trivial dollar amounts
- No buys from any insider suggests management is not aggressively signaling undervaluation, but this is normal for a post-IPO biotech with no near-term catalyst
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-MAZE-1788588557482 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | Insider Cluster | $26.37 $24.23 | ▼ −8.12% | ▼ −7.00% | $26.69 (+1.20%) |
Sep 4, 2026 27d ago | Insider Cluster | $26.37 $24.23 | ▼ −8.12% | ▼ −7.00% | $26.69 (+1.20%) |
Sep 3, 2026 29d ago | Insider Cluster | $25.87 $24.60 | ▼ −4.91% | ▼ −3.76% | $26.69 (+3.16%) |
Sep 2, 2026 29d ago | 144 | $25.87 $24.60 | ▼ −4.91% | ▼ −3.76% | $26.69 (+3.16%) |
Sep 1, 2026 4w ago | 144 | $26.72 $24.82 | ▼ −7.11% | ▼ −6.15% | $26.69 (−0.12%) |
Aug 17, 2026 6w ago | 3 | $29.13 $30.42 | ▲ +4.43% | ▲ +4.63% | $26.69 (−8.38%) |
Aug 11, 2026 7w ago | Press Release | $27.53 $29.75 | ▲ +8.06% | ▲ +8.51% | $26.69 (−3.06%) |
Aug 7, 2026 8w ago | Institutional Cluster | $28.65 $27.18 | ▼ −5.13% | ▼ −5.53% | $26.69 (−6.85%) |
Aug 5, 2026 8w ago | Insider Cluster | $27.81 $27.53 | ▼ −1.01% | ▼ −1.36% | $26.69 (−4.04%) |
Jul 2, 2026 13w ago | Insider Cluster | $31.26 $32.42 | ▲ +3.71% | ▲ +2.78% | $26.69 (−14.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access